The urinary excretion of frusemide and its metabolites by kidney transplant patients.
Urine from 5 renal transplant recipients treated with frusemide was analyzed for unchanged frusemide (F), glucuronidated frusemide (G) and 4-chloro-5-sulfamoylanthranilic acid (CSA) by HPLC. In 3 recipients, whose renal function recovered steadily and whose hepatic function was normal throughout, the ratio of frusemide to its metabolites, F/(F + G + CSA), increased steadily in conjunction with the recovery of renal function. In one patient, who received frusemide 200-400 mg/day i.v., the urinary CSA concentration was 64-102 micrograms X ml-1. In 2 patients who experienced shock and/or hepatic dysfunction after transplantation, the F/(F + G + CSA) ratio fluctuated.
Nakahama
H
H
Miwa
Y
Y
Yamaji
A
A
Orita
Y
Y
Fukuhara
Y
Y
Yanase
M
M
Kamada
T
T
Sonoda
T
T
Ishibasi
M
M
Ichikawa
Y
Y
D000328:Adult; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005665:Furosemide / Q000031:analogs & derivatives / Q000378:metabolism / Q000652:urine*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D062367:ortho-Aminobenzoates / Q000652:urine
D062367:ortho-Aminobenzoates; C036234:furosemide glucuronide; D005665:Furosemide; C010554:4-chloro-5-sulfamoylanthranilic acid